TEARS: Tear Electrochemical Alzheimer’s Recognition System 

At age 45, lifetime Alzheimer’s risk is 1 in 5 for women and 1 in 10 for men, yet only 20% of patients are diagnosed at the mild cognitive impairment stage. TEARS is a simple, non-invasive POCT biomarker device positioned to enable earlier diagnosis, support timely treatment, and preserve quality of life.